SARS-CoV-2
Showing NaN - NaN of 10
Lung Transplant Recipient, SARS-CoV-2, Immunosuppression Trial (mRNA-1273 (Moderna COVID-19 vaccine))
Active, not recruiting
- Lung Transplant Recipient
- +2 more
- mRNA-1273 (Moderna COVID-19 vaccine)
-
Los Angeles, CaliforniaUCLA Clinical Translational Research Center
Dec 13, 2022
SARS-CoV-2 Trial in Canada, United States (mRNA-1273, Placebo)
Recruiting
- SARS-CoV-2
- mRNA-1273
- +2 more
-
Birmingham, Alabama
- +89 more
Oct 7, 2022
COVID-19, SARS-CoV-2 Trial in Chile, Peru, United States (AZD1222, Placebo)
Active, not recruiting
- COVID-19
- SARS-CoV-2
- AZD1222
- Placebo
-
Phoenix, Arizona
- +83 more
Jul 13, 2022
SARS-CoV-2 Trial in Los Angeles (Family Risk Messaging, Personal Risk Messaging, Loss Protection)
Enrolling by invitation
- SARS-CoV-2
- Family Risk Messaging
- +3 more
-
Los Angeles, CaliforniaAltaMed Health
Jul 12, 2022
COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome) Trial in United States (Hydroxychloroquine Sulfate,
Completed
- COVID-19
- +3 more
- Hydroxychloroquine Sulfate
- Ascorbic Acid
-
Los Angeles, California
- +7 more
Dec 14, 2021
Acute Respiratory Distress Syndrome, SARS-CoV-2 Trial in United States (PLN-74809, Placebo)
Terminated
- Acute Respiratory Distress Syndrome
- SARS-CoV-2
- PLN-74809
- Placebo
-
Phoenix, Arizona
- +5 more
Oct 8, 2021
SARS-CoV-2-specific Immunity in Individuals Who Have Recovered
Active, not recruiting
- SARS-CoV-2
- COVID-19
- Sample collection
-
Birmingham, Alabama
- +52 more
Sep 3, 2021
Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection Trial in New Zealand, United States (biological, drug,
Unknown status
- Covid19
- +3 more
- Biological: oral polio vaccine
- +5 more
-
Los Angeles, California
- +9 more
Sep 5, 2020